Participated · Series C · Mar 2025

Navina builds an AI-powered clinical intelligence platform (an AI copilot) that turns fragmented patient data into concise patient profiles and actionable insights at every clinical touchpoint. The product natively integrates into clinician workflows to support decision-making across the care continuum and reduce administrative burden. Navina serves over 10,000 healthcare professionals across 1,300 clinics and supports care for more than three million patients, with an 86% weekly active usage rate. The company has partnerships with agilon health, InnovaCare Health, Millennium Physician Group, and Privia Health, and was recognized Best in KLAS 2025 for Clinician Digital Workflow. Navina plans to accelerate development of its proprietary AI to become a unified source of patient data and to expand platform capabilities from proactive population health management to point-of-care intervention. Financially, the company has raised $100 million to date after completing a $55 million Series C. Navina develops an AI-powered assistant platform that structures and summarizes complex medical data for primary care physicians at the point of care. Its models were trained on a curated dataset of imaging notes, consult notes, hospital notes, procedures and labs and the software integrates with existing electronic health records to surface potential diagnoses and quality or risk gaps. The company emphasizes fitting into existing clinical workflows and aims to expand its product into home, virtual and urgent care settings. Navina says it is HIPAA-compliant, has completed a third-party privacy audit and is in the final stages of SOC2 certification. The platform is used by "thousands" of clinicians and supporting staff; Navina currently has 65 employees and expects to have about 75 by year end. The team was founded by Ronen Lavi and Shay Perera, who previously led the Israel Defense Forces' AI lab and used that experience to build Navina's assistant systems. Navina builds an AI-powered clinical platform for primary care that consolidates disorganized patient data into an intuitive "Patient Portrait" logical grid to help physicians assess complex cases quickly. Led by co-founder and CEO Ronen Lavi, the platform is medically informed and has demonstrated measurable clinical and economic impact for multi-specialty and primary care physician groups nationwide. Adopters have seen increases in HCC-RAF (Risk Adjustment Factor) scores, which the company says translates into revenue. Navina intends to use new funding to accelerate investment in its AI technology and to expand within physician groups and the enterprise healthcare market. The company is based in Tel Aviv, Israel and had total funding to date of $22M following the Series A. Navina is a Tel Aviv, Israel–based developer of an AI-driven platform for primary care. The company uses medically-informed AI to replace disorganized patient data with a Patient Portrait — a logical grid that enables primary care physicians to assess cases in minutes. The platform is designed to reduce missed diagnoses and enhance financial performance for providers and payers. Navina's system has already been integrated into several large, multi-specialty physician groups in the United States. The company raised $7M in seed funding and intends to use the proceeds to advance R&D of its proprietary AI and machine learning platform. It also plans to drive business development initiatives to expand utilization within physician groups and the enterprise healthcare market.

Participated · Equity · Jul 2024

Magenta Medical is focused on developing miniaturized blood pumps intended to provide minimally invasive support to the native heart during acute episodes of dysfunction. Its lead product, the Elevate™ percutaneous left ventricular assist device (pLVAD), is in clinical trials for at least two indications: high-risk percutaneous coronary interventions (HR-PCI) and cardiogenic shock. The company plans to use the new funding to advance its U.S. clinical programs across multiple mechanical circulatory support (MCS) indications and to pursue FDA approval for the Elevate System in HR-PCI patients. Magenta is led by CEO Dr. David Israeli and is based in Kadima, Israel. The company positions its technology to support patients at risk of dangerously low blood pressure and compromised organ perfusion during acute cardiac events. Magenta Medical is a Kadima, Israel–based company developing miniaturized blood pumps to provide minimally-invasive support to the native heart. Its lead product, the Elevate percutaneous left ventricular assist device, is currently in clinical testing. The company intends to secure FDA approval for at least two indications: patients undergoing high-risk coronary interventions and patients with cardiogenic shock. Magenta plans to use new funding to advance the clinical programs of Elevate in the United States toward its first FDA approval. The company was founded by serial entrepreneurs Professor Ehud Schwammenthal and Yosi Tuval, who previously founded Ventor Technologies. Magenta is led by CEO Dr. David Israeli. Magenta Medical develops a catheter-based flow pump inserted on the venous side to help kidneys eliminate salt and relieve fluid buildup in heart-failure patients. The device delivers therapy for up to 24 hours and does not leave a permanent implant. Company executives say the therapy aims to reduce hospital readmissions and ICU stays tied to deteriorating kidney function. Magenta’s technology is already in clinical trials in Europe, and the current funds will be used to obtain a CE Mark. The firm plans to share European trial data with the FDA to determine a U.S. regulatory pathway and hopes to reach agreement with the agency on that clinical pathway. Magenta was founded in October 2012 by a cardiologist and a mechanical engineer; David Israeli is the company’s CEO. Magenta Medical develops novel therapeutic approaches to the treatment of congestive heart failure. The company is described in the article as pioneering a new therapeutic approach for CHF, a condition characterised as an epidemic in the Western world. Magenta was founded in October 2012 by CEO Prof. Ehud Schwammenthal and mechanical engineer Yosi Tuval and is based in Tel Aviv, Israel. The company raised $4M in seed funding from Pitango Venture Capital. As part of the investment, Pitango partner Dr. David Israeli will join Magenta's board of directors. No additional financial terms or use-of-proceeds details were disclosed in the article.

Led · Series A · Feb 2024

Vessi Medical has developed an IP-protected cryospray system purposely designed for hollow and humid organs as a novel, minimally invasive approach to treat non-muscle-invasive bladder cancer (NMIBC). The technology is positioned as an alternative to the invasive first-line therapy TURBT and has been used in a first-in-human study. Led by Founder and CEO Eyal Kochavi, the company aims to reduce side effects, improve patient outcomes, and lower healthcare costs relative to current surgical approaches. Vessi plans to use new funding to expand R&D capabilities and support clinical studies in Israel and the U.S. The company is also pursuing regulatory clearance to bring its treatment to patients and physicians. Vessi Medical develops an intravesical cryotherapy system for superficial (non‑muscle invasive) bladder cancer. Its core product is a minimally invasive system composed of a standalone console and a disposable device inserted transurethrally into the bladder. The company is led by CEO Eyal Kochavi and is advancing the technology to improve quality of life for NMIBC patients. Vessi raised $1.7M in funding to continue development of its device. The proceeds are intended to support the planned first‑in‑human study to demonstrate safety and efficacy in Q1 2021.

Participated · Seed · Aug 2023

Nevia Bio (formerly Gina Life) applies machine learning to proprietary protein-panel measurements from vaginal swabs to identify biomarker signatures for early and late-stage women’s diseases, notably ovarian cancer. The platform decodes information from vaginal secretions and links a novel biobank to a digital database to enable ML-driven feature identification. Since commencing activity in 2020, the company has run clinical trials and assembled a biobank of more than 900 vaginal-secretion samples from diverse populations and disease states. Nevia plans to use its recent funding to support clinical trials in ovarian cancer, expand its pipeline to additional indications in women’s health, and enhance its data science capabilities. The team is led by Dr. Inbal Zafir-Lavie and Dr. Shlomit Yehudai-Reshef. The company is based in Haifa, Israel.

Participated · Series A · Jul 2023

Append Medical is developing the Appligator™, a transcatheter device intended to completely close the left atrial appendage (LAA) without requiring any metal implants. The company plans to use recent funding to complete device development and to support a First‑in‑Human study of the Appligator™ for prevention of stroke in atrial fibrillation patients. Founded in 2018 by Dr. Zachi Berger based on an idea from Dr. Leonid Sternik of Sheba Medical Center, the company is led by CEO Nadav Agian. Append Medical is based in Or Yehuda, Israel, and is a portfolio company of the MEDX Xelerator incubator. The product positioning centers on offering a metal‑free alternative for LAA closure via a transcatheter procedure.